Quick Take DemeRx, an atai Life Sciences (atai) subsidiary focused on developing ibogaine for the treatment of opioid use disorder (OUD), just got approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase 1/2a clinical trial of DMX-1002. The approval will enable DemeRx to study DMX-1002 in recreational drug users…